Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $184.45
    +0.07 (+0.04%)

    Market Cap: $286.07B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AstraZeneca PLC (AZN) Earnings: Report Dates and Results

    Updated Oct 30, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, AstraZeneca reported EPS of $2.79, above the $2.60 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(25/37)
    Avg Surprise
    +4.61%
    Streak
    4 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$2.43
    Range$2.09 - $2.72
    18 analysts
    Revenue Consensus
    $17.18B
    Range$15.82B - $18.21B
    19 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    $15.98B
    Range$15.88B - $16.07B
    2 analysts

    Next Report

    Analysts' consensus for the quarter ending Dec 31, 2026 is 63.1% above the $1.49 reported for the quarter ended Dec 31, 2025.

    AZN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    AZN Earnings Call

    The latest AZN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, AZN beat 24, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $15.99B, up 5.3% from $15.19B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$2.79$2.60N/A+7.31%Beat+134.5%10 up, 0 downOct 30, 2026$15.99B
    Jun 30, 2026$2.63$2.50N/A+5.20%Beat+232.9%21 up, 0 downJul 27, 2026$15.38B
    Mar 31, 2026$1.29$1.27$1.25 - $1.29+1.57%Beat+3.2%21 up, 0 downApr 29, 2026$15.29B
    Dec 31, 2025$1.49$1.08$1.02 - $1.18N/AN/A+41.7%30 up, 1 downFeb 10, 2026$15.50B
    Sep 30, 2025$1.19$1.13$1.13 - $1.14+5.31%Beat+14.4%32 up, 1 downNov 6, 2025$15.19B
    Jun 30, 2025$0.79$0.88N/A-10.23%Miss-20.2%30 up, 2 downJul 29, 2025$14.46B
    Mar 31, 2025$1.25$1.12$1.09 - $1.13+11.61%Beat+21.4%31 up, 0 downApr 29, 2025$13.59B
    Mar 30, 2025$2.48$2.25N/A+10.22%Beat+140.8%N/AN/AApr 29, 2025$13.59B
    Dec 31, 2024$1.05$1.04N/A+0.96%Beat+43.8%N/AN/AFeb 6, 2025$14.89B
    Sep 30, 2024$1.04$1.03$0.98 - $1.12+0.97%Beat+19.5%30 up, 0 downNov 12, 2024$13.56B
    Jun 30, 2024$0.99$0.99$0.98 - $1.800.00%In line-8.3%41 up, 1 downJul 25, 2024$12.94B
    Mar 31, 2024$1.03$0.95$0.93 - $1.79+8.42%Beat+7.3%32 up, 0 downApr 25, 2024$12.68B
    Dec 31, 2023$0.73$0.76N/A-3.95%Miss+5.8%N/AN/AFeb 8, 2024$12.02B
    Sep 30, 2023$0.87$0.82N/A+6.10%Beat+3.6%10 up, 0 downNov 9, 2023$11.49B
    Jun 30, 2023$1.08$0.97$0.83 - $1.03+11.34%Beat+25.6%30 up, 0 downJul 28, 2023$11.42B
    Mar 31, 2023$0.96$0.82$0.82 - $1.75+17.07%Beat+1.1%41 up, 0 downApr 27, 2023$10.88B
    Dec 31, 2022$0.69$0.68N/A+1.47%Beat-17.9%N/AN/AFeb 9, 2023$11.21B
    Sep 30, 2022$0.84$0.75N/A+12.00%Beat+55.6%10 up, 0 downNov 10, 2022$10.98B
    Jun 30, 2022$0.86$1.04N/A-17.31%Miss+91.1%10 up, 0 downJul 29, 2022$10.77B
    Mar 31, 2022$0.95$1.15N/A-17.39%Miss+15.9%10 up, 1 downApr 29, 2022$11.39B
    Dec 31, 2021$0.84$0.99N/A-15.15%Miss+37.7%N/AN/AFeb 10, 2022$12.01B
    Sep 30, 2021$0.54$0.46N/A+18.68%Beat+17.4%2N/ANov 12, 2021$9.87B
    Jun 30, 2021$0.45$0.35N/A+30.43%Beat-6.2%1N/AJul 29, 2021$8.22B
    Mar 31, 2021$0.82$0.96N/A-14.58%Miss+54.7%1N/AApr 30, 2021$7.32B
    Dec 31, 2020$0.61$0.76N/A-19.74%Miss+155.7%N/AN/AFeb 11, 2021$7.41B
    Sep 30, 2020$0.46$0.48N/A-4.17%Miss-8.0%1N/ANov 5, 2020$6.58B
    Jun 30, 2020$0.48$0.40N/A+20.00%Beat+29.7%1N/AJul 30, 2020$6.28B
    Mar 31, 2020$0.53$0.49N/A+8.16%Beat+17.8%1N/AApr 29, 2020$6.35B
    Dec 31, 2019$0.24N/AN/AN/AN/A-70.8%N/AN/AFeb 14, 2020$6.66B
    Sep 30, 2019$0.50$0.41N/A+21.95%Beat+38.9%1N/AOct 24, 2019$6.41B
    Jun 30, 2019$0.37$0.31$0.28 - $0.31+19.35%Beat+5.7%2N/AJul 25, 2019$5.82B
    Mar 31, 2019$0.45$0.38N/A+18.42%Beat+67.7%3N/AApr 26, 2019$5.49B
    Dec 31, 2018$0.82N/AN/AN/AN/A+25.6%N/AN/AFeb 14, 2019$6.42B
    Sep 30, 2018$0.36$0.37N/A-2.70%Miss-35.7%N/AN/ANov 8, 2018$5.34B
    Jun 30, 2018$0.35$0.30N/A+16.67%Beat-20.5%2N/AJul 26, 2018$5.16B
    Mar 31, 2018$0.27$0.35$0.29 - $0.42N/AN/A-46.3%3N/AMay 18, 2018$5.18B
    Dec 31, 2017$0.65$0.56N/A+16.07%Beat+6.6%N/AN/AFeb 2, 2018$5.78B
    Sep 30, 2017$0.56$0.57$0.49 - $0.63-1.75%Miss-15.2%3N/ANov 9, 2017$6.23B
    Jun 30, 2017$0.44$0.42$0.42 - $0.42+4.76%Beat+4.8%2N/AJul 27, 2017$5.05B
    Mar 31, 2017$0.50$0.54N/A-7.41%Miss+4.2%1N/AApr 27, 2017$5.41B
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.72, up 14.8% from the year before. It was $2.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.72+14.8%
    Dec 31, 2024$4.11+12.9%
    Dec 31, 2023$3.64+9.0%
    Dec 31, 2022$3.34+26.0%
    Dec 31, 2021$2.65+27.4%
    Dec 31, 2020$2.08+33.5%
    Dec 31, 2019$1.56-13.1%
    Dec 31, 2018$1.79-16.5%
    Dec 31, 2017$2.15N/A
    Dec 31, 2016$2.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 15,000 words across 23 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202614,81123
    2026Q2Jun 30, 202613,44824
    2026Q1Mar 31, 202610,41424
    2025Q4Dec 31, 20257,59115
    2025Q3Sep 30, 20258,99323
    2025Q2Jun 30, 202510,19817
    2025Q1Mar 31, 20255,42110
    2024Q4Dec 31, 20246,01210

    2026Q3 Earnings Call

    Opening remarks

    Joris Silon Head of Investor Relations A warm welcome to AstraZeneca's 9 Months and Third Quarter 2026 Presentation Conference Call and Webcast for Investors and Analysts. I'm Joris Silon, Head of Investor Relations. And before I hand over to Pascal and members of our executive team, I would like to cover some housekeeping items. All of the materials presented today are available on our AstraZeneca Investor Relations website. Next slide, please. This slide contains our forward-looking statements, including the safe harbor provisions, which I would encourage you to take the time to read. We will be making comments on our performance using constant exchange rates, or CER, or financial numbers and other non-GAAP measures. A non-GAAP to GAAP reconciliation is contained within the results announcement. All numbers quoted are in millions of U.S. dollars unless stated otherwise. Next slide, please. This slide shows our agenda for today's call. Following our prepared remarks, we will open the line for questions. And as usual, we will try to address as many questions as we can during the allocated time. Although please limit the number of questions you ask to allow others a fair chance to participate in the Q&A. And with that, please advance to the next slide, and Pascal, over to you.

    Pascal Soriot CEO Thank you, Joris, and welcome, everybody. Next slide, please. I'm pleased to report that our strong growth momentum and pipeline delivery have continued through the first 9 months of 2026. This reflects the progress we are making across our strategic priorities and overall, the focus and the commitment of teams across our company. Total revenue grew 7% and core EPS increased 14%. Excluding Farxiga and Brilinta, total revenue grew 12%, demonstrating the underlying strength of our broad portfolio. Since our full year results in February, we've announced positive results from 12 Phase III programs, and we've achieved first approvals for 4 new medicines, including Etcamah in the U.S. This brings our total number of approved new molecular entities to 14 as we progress towards our goal of delivering 20 new medicines by 2030. We've also presented positive Phase III data for 3 new molecular entities: tozorakimab in COPD, efzimfotase alfa in HPP and sone-ve, our first wholly owned ADC, in Claudin 18.2 positive gastric cancer. With commercial momentum continuing and a deep late-stage pipeline advancing, we are increasingly confident in our ability to deliver our 2030 ambition as well as sustainable long-term growth through the next decade. Next slide, please. Our strong performance is underpinned by the breadth of our therapy areas and our geographical footprint. In the first 9 months, oncology, rare disease and R&I all delivered double-digit growth.

    Frequently Asked Questions About AZN

    Did AZN beat earnings estimates last quarter?

    Yes. AstraZeneca reported EPS of $2.79 for the quarter ended Sep 30, 2026, above the $2.60 estimate, a 7.31% surprise.

    What EPS do analysts expect from AZN next quarter?

    The consensus EPS estimate for AstraZeneca for the quarter ending Dec 31, 2026 is $2.43 from 18 analysts, with estimates from $2.09 to $2.72.

    How often does AZN beat earnings estimates?

    AstraZeneca beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +3.99%.